The platform is relatively new (launched June 2025), which explains the limited independent review presence
But when it comes to osteoarthritis, aging may be a bigger factor than obesity, so while we do see some impact from the rise of GLP-1 medications, this market isnt likely to suffer too much, in our opinion
[1] [5] Commonly prescribed GLP-1 receptor agonists in the UK include: Semaglutide (Ozempic for diabetes, Wegovy for weight management, Rybelsus as the only oral formulation) Dulaglutide (Trulicity) Liraglutide (Victoza for diabetes, Saxenda for weight management) Exenatide (Byetta, Bydureon) Lixisenatide (Lyxumia) Most of these medications are administered as subcutaneous injections (weekly or daily, depending on the formulation), with only semaglutide (Rybelsus) available as an oral tablet in the UK
For exclusive savings on your first order, visit getHLTH.com and enter the discount code KSL at checkout
So, which treatments are backed by solid evidence, and which ones are simply over hyped